# RonanRx: Personalized Peptide and GLP-1 Therapy Platform A vertically integrated pharmaceutical startup revolutionizing personalized medicine with software-driven manufacturing. - **Source:** [Hacker News: Launches](https://news.ycombinator.com) - **Published:** 2026-09-02 - **Original article:** - **On Brifing:** https://brifing.si/s/985d92be-e8f0-48ff-87ab-92c77395bda1 ## Founder's Background Lloyd previously built one of the largest US mask manufacturing operations during COVID, generating $50M revenue by applying software principles to physical production. His experience in vertical integration and regulated manufacturing directly informed RonanRx's approach to pharmaceuticals. The company represents his second Y Combinator-backed venture after his W10 batch software startup. ## Personal Health Journey After struggling with weight loss through extreme diets, Lloyd discovered GLP-1 medications. Beyond weight management, the treatment reduced compulsive behaviors and significantly improved his congenital heart condition - potentially delaying needed surgery by decades. This transformative personal experience revealed the limitations of standardized pharmaceutical approaches and inspired RonanRx's patient-specific model. ## Industry Problem Current pharmaceutical systems operate in silos: telehealth platforms, EHRs, prescriptions, and manufacturing exist as disconnected components. GLP-1 medications come in fixed doses despite patients' varied responses. While compounding pharmacies can customize, their manual processes lack integration with patient data and modern software efficiencies - creating suboptimal treatment experiences. ## Technical Solution RonanRx built an end-to-end platform handling prescription, formulation, compounding, testing, and delivery. Their software integrates medical records, wearable data, and treatment responses to enable dynamic dosing adjustments. The system maintains physician oversight while automating previously manual processes through digital workflows - creating medicine's first closed-loop feedback system. ## Business Model By controlling the entire stack from molecule to delivery, RonanRx eliminates middlemen markups, offering drugs at 3-10x lower prices than traditional channels. Revenue comes from direct-to-consumer medication sales rather than software licensing. The model mirrors Lloyd's mask manufacturing playbook - applying vertical integration to reduce costs while improving quality control. ## Initial Focus While launching with GLP-1s and peptides due to the founder's personal experience, the company views these as entry points into broader personalized medicine. The platform architecture supports expansion into other therapeutic areas requiring customized formulations. Early design accommodates strict pharmaceutical regulations while maintaining software agility. ## Regulatory Approach Operating in highly regulated pharma space, RonanRx combines software startup velocity with rigorous compliance. Their manufacturing facilities meet pharmaceutical standards while employing ML and computer vision learned from mask production. The model navigates complex drug compounding regulations by maintaining physician oversight at each treatment adjustment. ## Industry Implications RonanRx represents a fundamental shift from mass-produced drugs to software-enabled personalized medicine. Successful execution could pressure traditional pharma to adopt similar models while creating new standards for treatment efficacy. The approach particularly benefits therapies where patient response varies significantly - potentially expanding beyond metabolic to neurological and autoimmune conditions. ## Sources covering this story - https://news.ycombinator.com/item?id=49543530 — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._